Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 6/2011

01.06.2011 | Gynecologic Oncology

Ovarian malignant Mullerian mixed tumor (heterologous) whose epithelial component is composed predominantly of signet ring cell carcinoma

verfasst von: Tadashi Terada

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Ovarian malignant Mullerian mixed tumor (MMMT) (carcinosarcoma) is a relatively rare, very aggressive tumor.

Methods

Herein is presented an unusual case of heterologous MMMT with an epithelial element composed predominantly of signet ring cell carcinoma.

Results

A 60-year-old Japanese woman consulted our hospital because of a pelvic mass. Imaging modalities showed a huge tumor of the right ovary. Laparotomy was performed, and frozen section showed a malignant tumor. Therefore, hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and omentectomy were performed. On gross examination, the right ovarian tumor was solid, measuring 12 × 13 × 12 cm. The surface was smooth but bosselated. Histologically, the tumor was composed of epithelial and sarcomatous elements. Curiously, the epithelial element was composed predominantly of signet ring cell carcinoma. A small area showed tubular adenocarcinoma and poorly differentiated carcinoma. The sarcomatous element was homologous with spindle cell sarcoma with many mitotic cells. The signet ring cells had mucins. Immunohistochemically, the epithelial element was positive for cytokeratins, EMA, p53, CEA, CA19-9, and Ki-67 (labeling = 75%). The sarcomatous element was positive for vimentin, α-smooth muscle actin, p53, and Ki-67 (labeling = 36%), indicating that it was a leiomyosarcoma. Metastases were found in many lymph nodes and intravascular spaces in the peritoneum; the metastases were composed of epithelial elements.

Conclusion

To the best of our knowledge, there have been no descriptions in the English literature of MMMT composed predominantly of signet ring cell carcinoma. An MMMT in this case, should be differentiated from Krukenberg tumor, metastatic signet ring cell carcinoma, and signet ring stromal tumor.
Literatur
1.
Zurück zum Zitat McCluggage WG, Haller U, Kurman RJ, Kubik-Huch RA (2003) Mixed epithelial and mesenchymal tumours. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 245–249 McCluggage WG, Haller U, Kurman RJ, Kubik-Huch RA (2003) Mixed epithelial and mesenchymal tumours. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 245–249
2.
Zurück zum Zitat Rosai J (2004) Malignant mixed mullerian tumor (carcinosarcoma). In: Rosai J (ed) Rosai, Ackerman’s pathology, 9th edn. Mosby, St. Louis, pp 1599–1601 Rosai J (2004) Malignant mixed mullerian tumor (carcinosarcoma). In: Rosai J (ed) Rosai, Ackerman’s pathology, 9th edn. Mosby, St. Louis, pp 1599–1601
3.
Zurück zum Zitat Lee KR, Russell P, Tavassoli FA et al (2003) Malignant mullerin mixed tumor. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, p 133 Lee KR, Russell P, Tavassoli FA et al (2003) Malignant mullerin mixed tumor. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, p 133
4.
Zurück zum Zitat Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y (2002) Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int 52:740–746PubMedCrossRef Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y (2002) Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int 52:740–746PubMedCrossRef
5.
Zurück zum Zitat Terada T, Kawaguchi M (2005) Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med 206:271–275PubMedCrossRef Terada T, Kawaguchi M (2005) Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med 206:271–275PubMedCrossRef
6.
Zurück zum Zitat Hendrickson MR, Tavassoli FA, Kempson RL, McCluggage WG, Haller U, Kubik-Huch RA (2003) Mesenchymal tumours and related lesions. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 233–244 Hendrickson MR, Tavassoli FA, Kempson RL, McCluggage WG, Haller U, Kubik-Huch RA (2003) Mesenchymal tumours and related lesions. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 233–244
7.
Zurück zum Zitat Kiyakawa T, Young RH, Scully RE (2006) Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 30:277–299 Kiyakawa T, Young RH, Scully RE (2006) Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 30:277–299
8.
Zurück zum Zitat Holtz F, Hart WR (1982) Krukenberg tumors of the ovary: a clinicopathologic analysis of 27 cases. Cancer 50:2438–2447PubMedCrossRef Holtz F, Hart WR (1982) Krukenberg tumors of the ovary: a clinicopathologic analysis of 27 cases. Cancer 50:2438–2447PubMedCrossRef
9.
Zurück zum Zitat Prat J, Morice P (2003) Secondary tumours of the ovary. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 193–196 Prat J, Morice P (2003) Secondary tumours of the ovary. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 193–196
10.
Zurück zum Zitat Tavassoli FA, Fujii S, Mooney E et al (2003) Sex-cord stromal tumours. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 146–161 Tavassoli FA, Fujii S, Mooney E et al (2003) Sex-cord stromal tumours. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. IARA Press, Lyon, pp 146–161
Metadaten
Titel
Ovarian malignant Mullerian mixed tumor (heterologous) whose epithelial component is composed predominantly of signet ring cell carcinoma
verfasst von
Tadashi Terada
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 6/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1591-1

Weitere Artikel der Ausgabe 6/2011

Archives of Gynecology and Obstetrics 6/2011 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.